Sorry, you need to enable JavaScript to visit this website.

REVATIO® (sildenafil) Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use REVATIO safely and effectively. See full prescribing information for REVATIO.

REVATIO (sildenafil) tablets, for oral use
REVATIO (sildenafil) for oral suspension
REVATIO (sildenafil) injection, for intravenous use
Initial U.S. Approval: 1998

INDICATIONS AND USAGE

REVATIO is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with NYHA Functional Class II–III symptoms. Etiologies were idiopathic (71%) or associated with connective tissue disease (25%). (1)

Limitation of Use: Adding sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity. (1, 14)

DOSAGE AND ADMINISTRATION

  • Tablet and oral suspension: 5 mg or 20 mg three times a day, 4–6 hours apart; see full prescribing information for reconstitution instructions for the Powder for Oral Suspension (2.1, 2.3)
  • Injection: 2.5 mg or 10 mg three times a day administered as an intravenous bolus injection (2.2)

DOSAGE FORMS AND STRENGTHS

  • Tablets: 20 mg (3)
  • Injection: 10 mg /12.5 mL in a single use vial (3)
  • For Oral Suspension: 10 mg/mL (when reconstituted) (3)

CONTRAINDICATIONS

  • Use with organic nitrates or riociguat (4)
  • History of hypersensitivity reaction to sildenafil or any component of the tablet, injection, or oral suspension (4)

WARNINGS AND PRECAUTIONS

  • Increased mortality with increasing doses in pediatric patients. Not recommended for use in pediatric patients. (5.1)
  • Vasodilation effects may be more common in patients with hypotension or on antihypertensive therapy. (5.2)
  • Use in pulmonary veno-occlusive disease may cause pulmonary edema and is not recommended. (5.3)
  • Hearing or visual impairment: Seek medical attention if sudden decrease or loss of vision or hearing occurs. (5.5, 5.6)
  • Pulmonary hypertension secondary to sickle cell disease: REVATIO may cause serious vaso-occlusive crises. (5.9)

ADVERSE REACTIONS

Most common adverse reactions greater than or equal to 3% and more frequent than placebo were epistaxis, headache, dyspepsia, flushing, insomnia, erythema, dyspnea, and rhinitis. (6.1, 6.2)


To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

  • Concomitant alpha-blockers or amlodipine: Note additive blood pressure lowering effects. (7)
  • Use with ritonavir and other potent CYP3A inhibitors: Not recommended. (7, 12.3)
  • Concomitant PDE-5 inhibitors: Avoid use with Viagra or other PDE-5 inhibitors. (5.7)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 2/2020

Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No